LAUSR

Key Points Question Are reductions in cardiovascular disease risk produced by financial incentives placed on patients, physicians, or both to control low-density lipoprotein cholesterol levels worth the costs needed to achieve these health benefits? Findings In this model-based economic evaluation, incentives shared between patients and physicians had an incremental cost-effectiveness ratio of $60 000/quality-adjusted life-year. However, this result was sensitive to assumptions around the durations of low-density lipoprotein cholesterol level reductions and incentive payments. Meaning Shared incentives between patients and physicians appear to provide reasonable value (<$100 000/quality-adjusted life-year) for the health gains that they produce, although longer-term demonstrations are needed to show how long these low-density lipoprotein cholesterol level reductions persist.